Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most favorite drugs for the treatment of somatoform pain in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, or pain associated with other arthritides from unknown origin, as well as peripheral and axial spondyloarthritides. Thus, NSAIDs cover the entire area of the treatment of inflammatory pain in musculoskeletal disorders [1]. Regarding their effectiveness NSAIDs surpass other analgesics including opioids. Comparing the mean efficacy of different NSAIDs, no relevant differences can be found if the approved maximum daily dose is used for each NSAID. However, from the perspective of an individual patient, the effectiveness of different NSAIDs differs widely. Thus, the change to a different NSAID in case of insufficient pain relief still may reach the therapeutic goal.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mutschler E, Geisslinger G, Kroemer HK, Menzel S, Ruth P. Mutschler Arzneimittelwirkungen: Pharmakologie – Klinische Pharmakologie – Toxikologie. 9th ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2012.
Vandraas KF, Spigset O, Mahic M, Slordal L. Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly. Eur J Clin Pharmacol. 2010;66(8):823–9. PubMed Epub 2010/04/21. eng.
Tielemans MM, Eikendal T, Jansen JB, van Oijen MG. Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf. 2010;33(6):443–53. PubMed Epub 2010/05/22. eng.
Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain. 2000;85(1-2):169–82. PubMed.
Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;376(9736):173–9. PubMed Epub 2010/07/20. eng.
Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–79.
Griffin MR. High-dose non-steroidal anti-inflammatories: painful choices. Lancet. 2013;382(9894):746–8. PubMed NSAID!.
Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160(14):2093–9. PubMed Epub 2000/07/25. eng.
McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9):e1001098. PubMed Pubmed Central PMCID: PMC3181230. Epub 2011/10/08. eng.
GarcÃa RodrÃguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol. 2008;52(20):1628–36.
Fosbol EL, Gislason GH, Jacobsen S, Folke F, Hansen ML, Schramm TK, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther. 2009;85(2):190–7. PubMed Epub 2008/11/07. eng.
McGettigan P, Henry D. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med. 2013;10(2):e1001388. PubMed Pubmed Central PMCID: 3570554.
Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113(25):2906–13. PubMed Epub 2006/06/21. eng.
EMA. European Medicines Agency concludes action on COX-2 inhibitors. European Medicines Agency [Internet]. 2005; (Doc. Ref. EMEA/207766/2005). Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/01/news_detail_000969.jsp&mid=WC0b01ac058004d5c1.
Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. Am J Epidemiol. 2006;164(9):881–9. PubMed Epub 2006/09/29. eng.
Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, et al. NSAID use and progression of chronic kidney disease. Am J Med. 2007;120(3):280e1–7. PubMed Epub 2007/03/14. eng.
Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165(5):490–6. PubMed Epub 2005/02/16. eng.
Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006;296(13):1619–32. PubMed Epub 2006/09/14. eng.
Morrison A, Ramey DR, van Adelsberg J, Watson DJ. Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension. Curr Med Res Opin. 2007;23(10):2395–404. PubMed.
Chan CC, Reid CM, Aw TJ, Liew D, Haas SJ, Krum H. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens. 2009;27(12):2332–41. PubMed Epub 2009/11/06. eng.
Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):232–5. PubMed.
Bombardier C. An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Cardiol. 2002;89(6A):3D–9. PubMed Epub 2002/03/23. eng.
Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol. 2007;23(2):134–41. PubMed Epub 2007/02/03. eng.
Tramer MR, Williams JE, Carroll D, Wiffen PJ, Moore RA, McQuay HJ. Comparing analgesic efficacy of non-steroidal anti-inflammatory drugs given by different routes in acute and chronic pain: a qualitative systematic review. Acta Anaesthesiol Scand. 1998;42(1):71–9. PubMed.
Moore RA, Derry S, McQuay HJ. Topical agents in the treatment of rheumatic pain. Rheum Dis Clin North Am. 2008;34(2):415–32. PubMed Epub 2008/07/22. eng.
Derry S, Moore RA, Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2012;(9):CD007400-CD. PubMed PMID: MEDLINE:22972108.
Conaghan PG, Dickson J, Bolten W, Cevc G, Rother M. A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis. Rheumatology (Oxford). 2013;52(7):1303–12. PubMed.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Bolten, W.W. (2015). NSAIDs. In: Kampen, W., Fischer, M. (eds) Local Treatment of Inflammatory Joint Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-16949-1_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-16949-1_4
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-16948-4
Online ISBN: 978-3-319-16949-1
eBook Packages: MedicineMedicine (R0)